Pharma Mar Sau Stock Probability Of Bankruptcy
| 0RC6 Stock | 97.80 1.70 1.77% |
Pharma | Probability Of Bankruptcy |
Pharma Mar SAU Company probability of financial unrest Analysis
Pharma Mar's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Pharma Mar Probability Of Bankruptcy | Less than 28% |
Most of Pharma Mar's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharma Mar SAU is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Pharma Mar probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Pharma Mar odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Pharma Mar SAU financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Pharma Mar SAU has a Probability Of Bankruptcy of 28.0%. This is 34.24% lower than that of the Commercial Services & Supplies sector and significantly higher than that of the Industrials industry. The probability of bankruptcy for all United Kingdom stocks is 29.7% higher than that of the company.
Pharma Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharma Mar's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharma Mar could also be used in its relative valuation, which is a method of valuing Pharma Mar by comparing valuation metrics of similar companies.Pharma Mar is currently under evaluation in probability of bankruptcy category among its peers.
Pharma Mar Main Bankruptcy Drivers
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Net Debt | (39.5M) | (64.0M) | (107.2M) | (16.4M) | (18.8M) | (17.9M) | |
| Total Current Liabilities | 94.9M | 86.3M | 97.3M | 95.9M | 110.3M | 81.0M | |
| Non Current Liabilities Total | 132.6M | 104.1M | 73.0M | 51.9M | 59.7M | 78.1M | |
| Total Assets | 330.3M | 368.4M | 393.3M | 340.5M | 391.6M | 276.4M | |
| Total Current Assets | 245.7M | 295.2M | 275.2M | 252.6M | 290.5M | 175.4M | |
| Total Cash From Operating Activities | 278.9M | 25.7M | 38.3M | (13.4M) | (15.5M) | (14.7M) |
Pharma Fundamentals
| Return On Equity | 0.0032 | ||||
| Return On Asset | -0.0065 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 1.62 B | ||||
| Shares Outstanding | 221.28 M | ||||
| Shares Owned By Insiders | 26.79 % | ||||
| Shares Owned By Institutions | 7.79 % | ||||
| Price To Sales | 98.12 X | ||||
| Revenue | 158.15 M | ||||
| Gross Profit | 157.68 M | ||||
| EBITDA | 4.55 M | ||||
| Net Income | 1.14 M | ||||
| Total Debt | 43.67 M | ||||
| Book Value Per Share | 10.39 X | ||||
| Cash Flow From Operations | (13.45 M) | ||||
| Earnings Per Share | 5.03 X | ||||
| Number Of Employees | 509 | ||||
| Beta | -0.004 | ||||
| Market Capitalization | 16.39 B | ||||
| Total Asset | 340.52 M | ||||
| Retained Earnings | 142.22 M | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 340.52 M | ||||
| Last Dividend Paid | 0.65 |
About Pharma Mar Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharma Mar SAU's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Mar using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Mar SAU based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pharma Stock Analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.